To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with target immunoprophylaxis as postoperative adjuvant therapy for hepatocellular carcinoma (HCC)

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300072663

Enrollment

Unknown

Registered

2023-06-20

Start date

2023-06-21

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Interventions

Experimental group (TACE+TKI+PD-1):None

Control group (TACE):None

Eligibility

Sex/Gender

All

Age

18 Years to 150 Years

Inclusion criteria

Inclusion criteria: 1. Patients who were clinically diagnosed with HCC after surgery and confirmed by histological/cytological examination. 2. Men and women over 18 years old; 3. Postoperative patients have good liver function and physical fitness: 4. Without comprehensive treatment before enrollment, at least 3 cycles of comprehensive treatment were applied, and at least one efficacy evaluation was performed. 5.All patients provided written informed consent for treatment before enrollment.

Exclusion criteria

Exclusion criteria: 1. Palliative tumor resection; 2. Receiving other anti-recurrence therapy after surgery; 3. Known intrahepatic cholangiocarcinoma (ICC) or mixed hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma; 4. Incomplete clinical or follow-up data.

Design outcomes

Primary

Measure	Time frame
3-year OS rate;	—

Countries

china

Contacts

Public Contactfanwei, zhulifu

GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL

298088870@qq.com+86 139 8540 9773

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026